Skip to main content

Health condition · Clinically reviewed

Ampullary cancer, a rare periampullary tumour with a curative-intent path.

Not pancreatic cancer. A distinct disease with a distinct prognosis - and a stepped diagnostic and surgical pathway that, in the right hands, offers real hope of cure.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, ESMO, Pancreatic Cancer UK and peer-reviewed HPB sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including EUS-FNA, molecular subtyping and PRODIGE-24 adjuvant chemotherapy.

Key facts

Ampullary cancer at a glance.

The essentials in plain English - what it is, how it differs from pancreatic cancer, and why the histological subtype matters.

  • What it is

    A rare cancer of the ampulla of Vater - the tiny valve where the bile duct and pancreatic duct empty into the duodenum.

  • Not pancreatic cancer

    Distinct from pancreatic head, distal bile duct and duodenal cancers - even though the symptoms overlap and surgery is similar.

  • Better prognosis

    Five-year survival sits at roughly 30 to 45 percent after curative surgery - meaningfully better than pancreatic cancer at around 10 percent.

  • Two subtypes

    Intestinal-type behaves more like bowel cancer and does better; pancreatobiliary-type behaves more like pancreatic cancer and does worse.

  • Classic presentation

    Painless jaundice with a palpable, non-tender gallbladder - the Courvoisier sign - plus weight loss, pale stools and dark urine.

  • Curative option

    The Whipple procedure (pancreaticoduodenectomy) at a specialist HPB centre is the mainstay for resectable disease.

Why this guide matters

A distinct disease with a distinct plan.

Ampullary cancer is often lumped in with pancreatic cancer. It should not be. The three points below shape everything else on this page.

  • Not pancreatic cancer

    Prognosis, subtypes and chemotherapy differ. Being labelled correctly at the first MDT changes what treatment you are offered.

  • Subtype drives chemotherapy

    Intestinal-type does better with FOLFOX; pancreatobiliary-type is treated more like pancreatic cancer with gemcitabine-based regimens.

  • Volume matters for the Whipple

    A pancreaticoduodenectomy in a high-volume HPB centre is safer and gives better cancer outcomes than the same operation in a low-volume unit.

How the diagnosis is made

From painless jaundice to a staged, subtyped plan.

The steps a UK GP, gastroenterologist and HPB team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    History and Courvoisier check

    Painless jaundice, weight loss, acholic stools and dark urine - with examination for a palpable, non-tender gallbladder.

  2. 02

    Assessing

    Cholestatic liver bloods

    A rise in bilirubin, ALP and GGT out of proportion to ALT and AST points to a distal biliary obstruction.

  3. 03

    Assessing

    Tumour markers

    CA 19-9 and CEA - useful as a baseline and for monitoring, but not diagnostic on their own.

  4. 04

    Confirming

    Pancreas-protocol CT

    A dedicated multiphase CT of the pancreas and liver defines the mass, staging and vascular relationships.

  5. 05

    Confirming

    MRI and MRCP

    Adds detail on the biliary tree and pancreatic duct - especially the double-duct sign and any liver lesions.

  6. 06

    Confirming

    EUS-FNA and ERCP

    Endoscopic ultrasound with fine-needle aspiration is the gold standard for tissue; ERCP allows brushings, biopsy and biliary stenting.

  7. 07

    Staging

    PET-CT and molecular profiling

    PET-CT for distant staging where it changes management; tumour molecular profiling to guide adjuvant and metastatic therapy.

Typical timeline: from first jaundice to an HPB MDT plan in two to four weeks.

Symptoms

What ampullary cancer actually looks like.

The classic mix of painless jaundice, weight loss and altered stools - plus the specific features that point to the ampulla rather than the pancreas.

  • Painless jaundice

    Yellowing of the skin and eyes without abdominal pain - the classic presenting feature and a red flag for periampullary cancer.

  • Fluctuating jaundice

    Bilirubin that rises and falls as a friable tumour bleeds and sloughs - a feature suggestive of ampullary rather than pancreatic origin.

  • Courvoisier sign

    A palpable, non-tender gallbladder in a jaundiced patient - a distal biliary obstruction is likely malignant until proven otherwise.

  • Weight loss and anorexia

    Unintentional weight loss over weeks to months, often with early satiety and reduced appetite.

  • Acholic stools and dark urine

    Pale, putty-coloured stools and tea-coloured urine reflect obstructed bile flow into the gut.

  • Steatorrhoea

    Loose, oily, foul-smelling stools that are hard to flush - from combined biliary obstruction and pancreatic exocrine failure.

  • Iron-deficiency anaemia

    Occult bleeding from the ulcerating ampullary tumour can present as fatigue, breathlessness and microcytic anaemia on bloods.

  • Silver stools

    The intermittent silver stool - a mix of melaena from tumour bleeding and pale acholic stool - is a rare but classic sign of ampullary cancer.

Treatment

How ampullary cancer is treated in the UK.

Curative-intent surgery for resectable disease, subtype-directed chemotherapy after surgery, and molecularly informed treatment when disease is advanced.

  • Whipple procedure

    Pancreaticoduodenectomy at a specialist HPB centre - the curative-intent operation for resectable ampullary cancer, removing the head of pancreas, duodenum, gallbladder and distal bile duct.

  • Endoscopic ampullectomy

    For select benign ampullary adenomas and very early T1a intramucosal disease - an organ-preserving alternative in carefully chosen patients at expert centres.

  • Adjuvant chemotherapy - intestinal

    Capecitabine or FOLFOX after surgery for intestinal-type disease, informed by PRODIGE-24 and ESPAC-3 data.

  • Adjuvant chemotherapy - pancreatobiliary

    Gemcitabine with capecitabine after surgery for pancreatobiliary-type disease, which behaves more like pancreatic cancer.

  • First-line for metastatic disease

    Gemcitabine and cisplatin for pancreatobiliary subtype; FOLFOX for intestinal subtype - with targeted therapy where molecular profiling opens a door.

  • FAP surveillance and ampullectomy

    Familial adenomatous polyposis raises the risk of ampullary adenomas - regular upper GI surveillance and prophylactic ampullectomy prevent malignant change.

  • HPB multidisciplinary team

    HPB surgery, oncology, gastroenterology, radiology, pathology and specialist nurses agree the plan - centralised care improves outcomes.

  • Supportive care

    Biliary stenting, nutritional support, pancreatic enzyme replacement therapy (PERT) and psychological support run alongside every stage.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, international HPB society standards and landmark trials, current at the time of last review.

Key references

Guidelines and trials we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your HPB surgeon and oncologist know your scans, subtype and history - and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Pancreatic cancer in adults: diagnosis and management (NG85) - periampullary considerations.

  • ESMO Clinical Practice Guidelines. Biliary tract and ampullary cancers.

  • Pancreatic Cancer UK. Information on periampullary and ampullary cancer.

  • PRODIGE-24/CCTG PA.6 and ESPAC-3 trials - evidence base for adjuvant chemotherapy in periampullary disease.

Red flags

When ampullary cancer needs urgent attention.

Most of the disease is managed on a planned HPB pathway. These are the situations that are not - and where same-day or specialist input is needed.

  • Cholangitis

    Fever, rigors, jaundice and right upper quadrant pain (Charcot triad) needs urgent admission for antibiotics and biliary drainage.

  • Rapidly rising bilirubin

    A fast climb in bilirubin with itch and lethargy warrants urgent biliary decompression to protect the liver and enable further treatment.

  • GI bleeding from the tumour

    Melaena, haematemesis or sudden anaemia from an ulcerating ampullary tumour needs urgent endoscopic assessment.

  • Gastric outlet obstruction

    Persistent vomiting, early satiety and weight loss can reflect duodenal invasion - a red flag needing prompt imaging and endoscopic review.

  • Suspected metastatic disease

    New back pain, ascites, liver capsule pain or a hard supraclavicular node should prompt urgent staging.

  • Post-Whipple complications

    Fever, tachycardia, abdominal pain or bile leak after surgery are surgical emergencies - contact the HPB team immediately.

  • Pancreatic exocrine failure

    Ongoing steatorrhoea, weight loss and fat-soluble vitamin deficiency need pancreatic enzyme replacement therapy and dietetic input.

  • Venous thromboembolism

    Pancreatobiliary cancers are highly thrombogenic - new leg swelling or breathlessness needs same-day assessment.

  • FAP with ampullary adenoma

    Any FAP patient with a rising adenoma grade at the ampulla should be discussed at an HPB MDT for ampullectomy or Whipple.

Living with it

A serious diagnosis, with a curative path.

Four things that make the biggest difference across the year after diagnosis - the right centre, real recovery time, enzyme replacement and structured follow-up.

A quiet reminder

Ask questions, and ask for the specialist nurse.

Your HPB clinical nurse specialist is the person who joins up surgery, oncology, dietetics and psychological support. Use them.

  1. 01 Centre

    Insist on a specialist HPB centre

    Whipple outcomes are meaningfully better in high-volume hepatopancreatobiliary units - it is reasonable and expected to ask for one.

  2. 02 Recovery

    Give recovery real time

    A Whipple is major surgery. Expect eight to twelve weeks before you feel like yourself, with gradual return to normal activity.

  3. 03 Nutrition

    PERT with every meal and snack

    Pancreatic enzyme replacement therapy taken with every meal and snack protects weight, energy and quality of life.

  4. 04 Follow-up

    Structured surveillance

    CT, tumour markers and clinic review on a set schedule - so any recurrence is picked up early when it is most treatable.

Frequently asked

Everything we get asked about ampullary cancer.

Quick answers on how it differs from pancreatic cancer, subtypes, the Whipple and FAP surveillance.

  • What is ampullary cancer?

    A rare cancer arising from the ampulla of Vater, the small valve where the common bile duct and pancreatic duct enter the duodenum. It is one of four periampullary cancers, alongside pancreatic head, distal bile duct and duodenal cancers, and it is treated as a distinct disease with a distinct prognosis.

  • Is ampullary cancer the same as pancreatic cancer?

    No. They arise in the same anatomical area and often need the same operation, but ampullary cancer starts in the ampulla itself and typically has a much better prognosis. Five-year survival after curative Whipple surgery is around 30 to 45 percent for ampullary cancer, compared with around 10 percent for pancreatic cancer overall.

  • Why does the histological subtype matter so much?

    Ampullary tumours split into intestinal-type, which behaves like bowel cancer and does better, and pancreatobiliary-type, which behaves like pancreatic cancer and does worse. The subtype, confirmed on biopsy and immunohistochemistry, drives the choice of adjuvant and metastatic chemotherapy.

  • What is the Courvoisier sign?

    A palpable, non-tender gallbladder in a jaundiced patient. Courvoisier law says this combination makes gallstones unlikely and points to a malignant distal biliary obstruction - such as pancreatic head, distal cholangiocarcinoma or ampullary cancer - until proven otherwise.

  • What does the Whipple procedure involve?

    Pancreaticoduodenectomy removes the head of the pancreas, the duodenum, the gallbladder, the distal bile duct and part of the stomach in some cases, then reconstructs the digestive tract. It is a major operation performed only at specialist HPB centres, with a hospital stay of one to two weeks and a recovery measured in months.

  • What about ampullary adenomas in FAP?

    People with familial adenomatous polyposis are at high lifetime risk of ampullary adenomas and cancer. Guidelines recommend regular upper GI surveillance with a side-viewing endoscope, biopsy of concerning lesions, and endoscopic or surgical ampullectomy for advanced adenomas to prevent malignant transformation.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.